CJC-1295 Side Effects: What's Known, Including the FDA Category 2 History

Short answer: In the human studies that exist, CJC-1295 was well tolerated — two placebo-controlled trials reported no serious adverse reactions. The effects injectable users mention most are mild and familiar to this class: injection-site reactions, water retention, flushing. The strip format has not been formally studied.

Most side-effect pages on this keyword read like warning labels. The actual record is more interesting — and more reassuring — than that, as long as you separate three things the SERP usually blurs: what controlled human studies found, what injectable users commonly report, and what the federal record actually says. Compound background lives in the CJC-1295 + Ipamorelin pillar.

What the human studies found

CJC-1295 has something many peptides don't: real placebo-controlled human trials. In the DAC pharmacology program (Teichman et al., 2006, PMID 16352683) — two randomized, placebo-controlled, double-blind, ascending-dose trials in healthy adults — a single subcutaneous dose raised mean GH two- to ten-fold for at least six days and IGF-I 1.5- to 3-fold for nine to eleven days, with an estimated half-life of 5.8–8.1 days [published human data — injectable DAC form].

The sentence that matters most on this page: no serious adverse reactions were reported, and the authors described the compound as safe and relatively well tolerated, particularly at the 30 or 60 µg/kg doses. These were small, short, healthy-volunteer studies — but they were controlled, placebo-compared, and genuinely reassuring within their scope.

What injectable users commonly report

Outside the trials, the recurring themes in injectable clinical use are injection-site reactions, water retention, and flushing — typically described as mild and transient [published human data — injectable route] [user reports — unverified]. One honest scoping note: all of these data points come from the injectable route, where the full dose reaches the bloodstream. They describe that route — they don't predict the strip's profile in either direction.

The FDA record — an active, moving story

Here's the federal record, stated precisely and dated. CJC-1295 was nominated for the 503A Bulks List and placed in Category 2 — the bucket for bulk substances the FDA flagged as raising significant safety risks. The nominators then withdrew, CJC-1295 was removed from Category 2, and the FDA took the five CJC-1295-related substances (free base, acetate, and the three DAC salts) up on its own initiative. At the December 4, 2024 Pharmacy Compounding Advisory Committee meeting, the FDA proposed that none of the five be included on the bulks list, citing evidence-sufficiency gaps: physicochemical characterization, no historical compounding-use data, nonclinical signals it wanted resolved, and limited clinical safety data.

Read that the way it was written: an evidence-sufficiency determination about compounding eligibility — not a verdict that the compound harms people. And the bigger picture keeps moving: the federal re-examination of this entire peptide category is active (at the July 2026 PCAC, several related peptides were recommended toward the bulks list), and restrictions in this space have been loosening as the process matures. Our standing references are BPC-157's FDA status explainer, the FDA panel July 2026 recap, and the full corrected record in is CJC-1295 legal in 2026. This article is stamped with a review date for exactly that reason.

The honesty passage

One bounded passage, because you deserve it plainly: no published human safety or pharmacokinetic data exists for sublingual CJC-1295 in any format — the strip's profile is unstudied in both directions — and the FDA's advisory process did recommend against clearing the compound for compounding. If your personal bar is a compound with a settled regulatory and long-term safety record, CJC-1295 doesn't meet that bar today, and the right move is to bring the FDA record to a licensed provider and decide there. For the pair's other half, see ipamorelin side effects, and for class-wide context, peptide side effects. That's the complete caveat — stated once.

How it's sold here

There's no standalone CJC-1295 SKU in the catalog. It lives inside the Strength combo — CJC-1295 250 mcg plus Ipamorelin 250 mcg per strip, 20-count, Citrus — openly stocked at $145 per box on the Strength strip page. The format question is covered in does sublingual CJC-1295 work.

The bottom line

CJC-1295's safety story is better than its reputation: placebo-controlled human trials with no serious adverse reactions, a mild and well-characterized side-effect pattern on the injectable route, and a federal record that is public, precise, and still evolving as the whole category gets re-examined. The strip format adds the usual honest asterisk — unstudied — but the foundation underneath this compound is controlled human data, not rumor. If that profile fits your risk comfort, order and start the conversation with the team.

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any new product. Individual results vary.